Pa. Pharma Ruling Opens New Front In Mass Tort Battles
By Dan Packel (January 23, 2014, 7:00 PM EST) -- A Pennsylvania Supreme Court ruling that pharmaceutical companies can be held liable for negligence in the design and marketing of drugs delivers a substantial new tool to plaintiffs in a state known as a hotbed for mass tort litigation, experts said Thursday.
The court on Tuesday rejected Pfizer Inc. subsidiary Wyeth Ltd.'s premise that under Pennsylvania law, pharmaceutical companies had immunity from all negligence claims beyond the two areas it was willing to concede: manufacturing defects and inadequate warnings. Plaintiffs attorneys cast the high court's 4-2 decision in a case over the now-discontinued diet drug Redux as a clear and resounding victory for claimants...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!